AGP Picks
View all

HYQURE expands biopharma quality control kit portfolio

Oct. 9, 2026
HYQURE expands biopharma quality control kit portfolio
By AI, Created 08:31 UTC, Oct 09, 2026, AGP -

HYQURE Biological Technology Co., Ltd. is highlighting its residual DNA, microbial and safety detection kits as biopharma makers face tighter quality-control demands across biologics, vaccines, viral vectors and cell and gene therapies. The company says the portfolio is built to support testing from development through manufacturing and regulatory review.

Why it matters: - Biopharmaceutical makers need analytical tools that can help assess residual impurities, contamination risk and product safety across increasingly complex production platforms. - Host cell residual DNA, microbial contamination and viral-safety concerns can affect process control, product characterization and regulatory documentation. - A broader kit portfolio can help laboratories match different assays to different stages of development, manufacturing and release testing.

What happened: - HYQURE Biological Technology Co., Ltd. is positioning its HyPrecise® detection-kit line for biopharmaceutical quality control and biosafety testing. - The company offers Host Cell Residual DNA Detection Kits, Microbial Detection Kits, Safety Detection Kits and Host Cell Residual Protein Detection Kits. - HYQURE says its products support biopharmaceutical development, large-molecule drugs, and cell and gene therapies. - The company is based in Jiashan, Jiaxing, Zhejiang, China, and lists an address in Pudong New Area, Shanghai, China. - More information is available on the company's official website.

The details: - HYQURE's residual DNA portfolio covers host systems including Chinese hamster ovary (CHO) cells, HEK293 cells, Escherichia coli, Pichia pastoris, Vero cells and human cells. - The company also lists residual DNA fragment analysis products for selected host systems and sample-preparation solutions for DNA detection workflows. - The product line uses fluorescent-probe qPCR methods for residual DNA testing, paired with nucleic-acid extraction products. - The article says qPCR can quantify specific nucleic-acid targets when the assay design and calibration strategy are appropriate. - Laboratories are expected to review target specificity, analytical sensitivity, sample recovery, interference and other performance characteristics before adoption. - Technical documentation can include intended host-cell target, sample types, quantification range, limit of detection, specificity, precision, accuracy, recovery, stability and operating conditions. - The article says published specifications are only an initial reference and do not replace suitability assessment in the user's own process. - HYQURE also provides microbial testing products, including tools related to mycoplasma detection and bacterial or fungal DNA analysis. - Mycoplasma testing is particularly relevant in cell culture-based manufacturing because contamination can be difficult to identify by visual inspection alone. - HYQURE's safety portfolio includes assays for viral and gene-therapy applications, including testing for replication-competent viral contaminants and selected viral-related targets. - The company says customers can review documentation, certifications, accreditations, audits and product-specific performance records before qualifying a kit.

Between the lines: - The kit portfolio is aimed at labs that need one supplier for multiple assay categories, but each assay still has to be qualified for its own use case. - The emphasis on documentation and verification reflects how heavily biopharma buyers weigh performance data, workflow fit and regulatory readiness. - The company's broader messaging suggests it is trying to position itself as a support provider across development, not just a reagent vendor. - The article notes that no single assay can replace a full quality system or detect every contaminant.

What's next: - Labs evaluating HYQURE kits will likely compare each product's target, sample matrix, controls, storage needs, shelf life and method-transfer support against their own workflows. - Buyers may also verify whether additional validation, qualification or transfer work is needed before using a kit in a regulated setting. - As biologics and advanced therapies become more complex, demand is expected to stay strong for targeted assays that can support process monitoring and quality decisions.

The bottom line: - HYQURE is using its residual DNA, microbial and safety-testing lineup to compete for a growing slice of biopharma quality control, where documentation and fit-for-purpose performance matter as much as the assay itself.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

China Arts & Entertainment Daily

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

China Arts & Entertainment Daily

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.